These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 15180544)

  • 1. HIV-resistance to viral entry inhibitors.
    Menéndez-Arias L; Esté JA
    Curr Pharm Des; 2004; 10(15):1845-60. PubMed ID: 15180544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical resistance to enfuvirtide does not affect susceptibility of human immunodeficiency virus type 1 to other classes of entry inhibitors.
    Ray N; Harrison JE; Blackburn LA; Martin JN; Deeks SG; Doms RW
    J Virol; 2007 Apr; 81(7):3240-50. PubMed ID: 17251281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Escape from human immunodeficiency virus type 1 (HIV-1) entry inhibitors.
    De Feo CJ; Weiss CD
    Viruses; 2012 Dec; 4(12):3859-911. PubMed ID: 23342377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular basis of human immunodeficiency virus type 1 drug resistance: overview and recent developments.
    Menéndez-Arias L
    Antiviral Res; 2013 Apr; 98(1):93-120. PubMed ID: 23403210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Escape of HIV-1 from a small molecule CCR5 inhibitor is not associated with a fitness loss.
    Anastassopoulou CG; Marozsan AJ; Matet A; Snyder AD; Arts EJ; Kuhmann SE; Moore JP
    PLoS Pathog; 2007 Jun; 3(6):e79. PubMed ID: 17542646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natural variation in the V3 crown of human immunodeficiency virus type 1 affects replicative fitness and entry inhibitor sensitivity.
    Lobritz MA; Marozsan AJ; Troyer RM; Arts EJ
    J Virol; 2007 Aug; 81(15):8258-69. PubMed ID: 17522224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients.
    Labrosse B; Morand-Joubert L; Goubard A; Rochas S; Labernardière JL; Pacanowski J; Meynard JL; Hance AJ; Clavel F; Mammano F
    J Virol; 2006 Sep; 80(17):8807-19. PubMed ID: 16912327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resistance and replicative capacity of HIV-1 strains selected in vivo by long-term enfuvirtide treatment.
    Menzo S; Castagna A; Monachetti A; Hasson H; Danise A; Carini E; Bagnarelli P; Lazzarin A; Clementi M
    New Microbiol; 2004 Apr; 27(2 Suppl 1):51-61. PubMed ID: 15646065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SHIVA - a web application for drug resistance and tropism testing in HIV.
    Riemenschneider M; Hummel T; Heider D
    BMC Bioinformatics; 2016 Aug; 17(1):314. PubMed ID: 27549230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infectivity and replication capacity of drug-resistant human immunodeficiency virus type 1 variants isolated during primary infection.
    Simon V; Padte N; Murray D; Vanderhoeven J; Wrin T; Parkin N; Di Mascio M; Markowitz M
    J Virol; 2003 Jul; 77(14):7736-45. PubMed ID: 12829813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enfuvirtide resistance mutations: impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization.
    Reeves JD; Lee FH; Miamidian JL; Jabara CB; Juntilla MM; Doms RW
    J Virol; 2005 Apr; 79(8):4991-9. PubMed ID: 15795284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV entry inhibitors: progress in development and application.
    Lai WH; Huang L; Chen CH
    Yao Xue Xue Bao; 2010 Feb; 45(2):131-40. PubMed ID: 21348414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization and structural analysis of HIV-1 integrase conservation.
    Ceccherini-Silberstein F; Malet I; D'Arrigo R; Antinori A; Marcelin AG; Perno CF
    AIDS Rev; 2009; 11(1):17-29. PubMed ID: 19290031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emergence of a drug-dependent human immunodeficiency virus type 1 variant during therapy with the T20 fusion inhibitor.
    Baldwin CE; Sanders RW; Deng Y; Jurriaans S; Lange JM; Lu M; Berkhout B
    J Virol; 2004 Nov; 78(22):12428-37. PubMed ID: 15507629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance to enfuvirtide, the first HIV fusion inhibitor.
    Greenberg ML; Cammack N
    J Antimicrob Chemother; 2004 Aug; 54(2):333-40. PubMed ID: 15231762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential virus evolution in blood and genital tract of HIV-infected females: evidence for the involvement of drug and non-drug resistance-associated mutations.
    Tirado G; Jove G; Kumar R; Noel RJ; Reyes E; Sepulveda G; Yamamura Y; Kumar A
    Virology; 2004 Jul; 324(2):577-86. PubMed ID: 15207642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Naturally occurring resistance mutations to HIV-1 entry inhibitors in subtypes B, C, and CRF31_BC.
    Araújo LA; Junqueira DM; de Medeiros RM; Matte MC; Almeida SE
    J Clin Virol; 2012 May; 54(1):6-10. PubMed ID: 22336085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Basic approaches to anti-HIV resistance].
    Baba M
    Nihon Rinsho; 2002 Apr; 60(4):763-8. PubMed ID: 11968785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV entry inhibitors: a new generation of antiretroviral drugs.
    Krambovitis E; Porichis F; Spandidos DA
    Acta Pharmacol Sin; 2005 Oct; 26(10):1165-73. PubMed ID: 16174430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.